Market Analysis and Price Projections for NDC: 16729-0440 (Cinacalcet)
Introduction to Cinacalcet
Cinacalcet, with the NDC code 16729-0440, is a medication manufactured by Accord Healthcare Inc. and is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD)[5].
Current Market Context
Prescription Drug Price Trends
The pharmaceutical market, particularly in the U.S., has seen significant price increases over the past few years. In 2022, the average price increase for prescription drugs was nearly $150 per drug in January and $250 in July, representing 10% and 7.8% increases, respectively[2].
Geographic Price Disparities
Prices for prescription drugs in the U.S. are notably higher compared to other regions. By 2022, prices in the U.S. were 5.5 times those in the OECD (excluding the U.S.) and 7.7 times prices in the rest of the world (excluding the U.S.)[4].
Market Size and Growth
Global Prescription Drug Market
The global prescription drug market has seen growth in both sales revenues and volumes over the past six years. However, the U.S. market stands out with an average price increase of 14% between 2017 and 2022, contrasting with decreases in other regions[4].
Volume and Revenue Growth
While the volume of prescription drugs grew 8% in the U.S. between 2017 and 2022, the sales revenues grew at a much higher rate, indicating a significant impact of price increases on revenue growth[4].
Pricing and Access Challenges
Industry Perspectives
C-suite executives in the life sciences industry identify pricing and access to drugs as the most significant issues facing the sector. Nearly half of the executives surveyed expect these issues to significantly impact their strategies in 2025[3].
Price Increases and Affordability
High prescription drug prices create affordability challenges for patients and the healthcare system. The frequent price increases, especially in January and July, exacerbate these challenges[2].
Specifics of Cinacalcet Pricing
Current Pricing
As of the latest data, there is no specific information on the current price of Cinacalcet (NDC: 16729-0440) provided in the sources. However, given the general trend of prescription drug price increases, it is likely that Cinacalcet has experienced price adjustments in line with industry norms.
Manufacturer and Market Position
Accord Healthcare Inc., the manufacturer of Cinacalcet, is a significant player in the generic and biosimilar market. The company's portfolio includes a range of medications, and their pricing strategies are influenced by market competition, regulatory environments, and the patent landscape[1].
Price Projections
Short-Term Projections
Given the historical data, it is reasonable to expect that Cinacalcet will follow the industry trend of price increases, particularly in January and July. The average price increase for prescription drugs in these months suggests that Cinacalcet could see a price rise of around 10% in January and 7.8% in July, aligning with the broader market trends[2].
Long-Term Projections
Over the long term, the pricing of Cinacalcet will be influenced by several factors, including:
- Competition from Generics and Biosimilars: As patents expire, the entry of generic and biosimilar competitors can drive prices down. However, this is balanced by the fact that many high-revenue products are facing a patent cliff, leading to potential mergers and acquisitions to maintain market share[3].
- Regulatory Changes: Any changes in regulatory policies, especially those aimed at controlling drug prices, could impact the pricing strategy for Cinacalcet.
- Market Demand and Supply: The demand for treatments of secondary hyperparathyroidism and the supply chain dynamics will also play a role in determining the long-term price trajectory.
Impact of External Factors
Inflation and Economic Conditions
The recent high rate of general inflation, as indicated by the Consumer Price Index (CPI-U), can influence drug prices. In 2022, the CPI-U increased by 8.5% between July 2021 and July 2022, which was slightly above the average July 2022 price increase for prescription drugs[2].
Technological and Scientific Advancements
Advances in genomics, biomarkers, and personalized medicine are expected to drive innovation in the life sciences industry. While these advancements can improve treatment efficacy and reduce side effects, they may also lead to higher development costs, which could be reflected in drug prices[3].
Key Takeaways
- Price Increases: Cinacalcet is likely to experience price increases in line with industry trends, particularly in January and July.
- Geographic Disparities: Prices in the U.S. are significantly higher than in other regions.
- Market Growth: The global prescription drug market is growing, but the U.S. market is driven more by price increases than volume growth.
- External Factors: Inflation, regulatory changes, and technological advancements will influence the long-term pricing strategy for Cinacalcet.
FAQs
-
What is Cinacalcet used for?
Cinacalcet is used for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD)[5].
-
Who manufactures Cinacalcet with the NDC code 16729-0440?
Cinacalcet with the NDC code 16729-0440 is manufactured by Accord Healthcare Inc.[5].
-
What are the typical times of year when prescription drug prices increase?
Prescription drug prices typically increase in January and July, with the greatest number of increases occurring in January[2].
-
How do U.S. prescription drug prices compare to other regions?
U.S. prescription drug prices are significantly higher, being 5.5 times those in the OECD (excluding the U.S.) and 7.7 times prices in the rest of the world (excluding the U.S.)[4].
-
What factors influence the long-term pricing of Cinacalcet?
Long-term pricing of Cinacalcet is influenced by competition from generics and biosimilars, regulatory changes, market demand and supply, and technological and scientific advancements[3][4].
Sources
-
Accord Healthcare Inc. - List of Drugs - NDC Labeler/Manufacturer
https://www.findacode.com/ndc/labelers/Accord_Healthcare_Inc.--16729
-
Price Increases for Prescription Drugs, 2016-2022 - ASPE
https://aspe.hhs.gov/sites/default/files/documents/e9d5bb190056eb94483b774b53d512b4/price-tracking-brief.pdf
-
2025 life sciences outlook | Deloitte Insights
https://www2.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2025-life-sciences-executive-outlook.html
-
International Market Size and Prices - ASPE
https://aspe.hhs.gov/sites/default/files/documents/4326cc7fe43bc11770598cf2a13f478c/international-market-size-prices.pdf
-
Cinacalcet tablet, film coated - DailyMed
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bad4e06-c0a1-4123-83c2-67d3b081e8a9
